CCR8 depletion reverses resistance to radiotherapy and PD-1 blockade in preclinical head and neck cancer
Depleting CCR8-positive regulatory T cells improved locoregional control and reversed resistance to radiotherapy plus anti-PD-1 in mouse head and neck cancer models.